Per Clauson

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

Kjeld Hermansen, Melanie J. Davies, Tadeusz Dereziński et al. · Diabetes Care · 2006 · 629 citations · Full text

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes

Athena Philis‐Tsimikas, G. Charpentier, Per Clauson et al. · Clinical Therapeutics · 2006 · 279 citations

Insulin Resistance, Metabolic Syndrome, Once-daily Insulin Detemir +10

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

P. Damsbo, Per Clauson, Thomas Marbury et al. · Diabetes Care · 1999 · 119 citations

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: <scp>A</scp> 26‐week, randomized, controlled, <scp>P</scp>an‐<scp>A</scp>sian, treat‐to‐target trial

Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo et al. · Journal of Diabetes Investigation · 2013 · 102 citations · Full text

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes

Kohei Kaku, Maria Rasmussen, Per Clauson et al. · Diabetes Obesity and Metabolism · 2009 · 89 citations